| Title |
Drug therapy for acquired pendular nystagmus in multiple sclerosis
|
|---|---|
| Published in |
Journal of Neurology, November 1996
|
| DOI | 10.1007/pl00007728 |
| Pubmed ID | |
| Authors |
M. Starck, H. Albrecht, W. Pöllmann, A. Straube, M. Dieterich |
| Abstract |
Acquired pendular nystagmus (APN) is regularly accompanied by oscillopsia and impairment of static visual acuity. Therapeutic approaches to APN remain controversial, and there is no generally accepted therapeutic approach. We tested 14 patients who had suffered from APN caused by multiple sclerosis for several years; 12 patients presented with fixational pendular nystagmus (increasing during fixation) and 2 with spontaneous pendular nystagmus. All 11 patients with fixational pendular nystagmus who were given memantine, a glutamate antagonist, experienced complete cessation of the nystagmus. In contrast, scopolamine caused no (6 of 8) or only a minor (10-50%) reduction of the nystagmus (2 of 8). It was concluded that memantine is a safe treatment option for APN. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| Unknown | 34 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 17% |
| Researcher | 5 | 14% |
| Other | 4 | 11% |
| Professor | 3 | 9% |
| Professor > Associate Professor | 3 | 9% |
| Other | 9 | 26% |
| Unknown | 5 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 29% |
| Agricultural and Biological Sciences | 6 | 17% |
| Psychology | 5 | 14% |
| Neuroscience | 4 | 11% |
| Physics and Astronomy | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 7 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2023.
All research outputs
#2,202,166
of 25,374,647 outputs
Outputs from Journal of Neurology
#357
of 4,964 outputs
Outputs of similar age
#769
of 26,995 outputs
Outputs of similar age from Journal of Neurology
#1
of 5 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,964 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 26,995 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them